Bellerophon Therapeutics, Inc. (BLPH)
| Previous close | 0.0586 |
| Open | 0.0522 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1400 |
| Day's range | 0.0522 - 0.0612 |
| 52-week range | 0.0290 - 11.1500 |
| Volume | |
| Avg. volume | 43,400 |
| Market cap | 716,830 |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeu
- GlobeNewswire
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023. “We are pleased with the prog
- GlobeNewswire
Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
Pivotal top-line data readout expected in mid-2023WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial l
